Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Daiichi Sankyo looking to sell OTC drug unit for about $900 million - Nikkei Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2019 | 01:04am EDT

TOKYO (Reuters) - Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

Reuters reported earlier this year that Japan's fourth-biggest drugmaker by sales had hired JPMorgan to advise on the potential sale of the unit, Daiichi Sankyo Healthcare.

The company denied it was negotiating a sale.

"Although Daiichi Sankyo is constantly examining the potential for a variety of strategic developments with the aim of sustainable business growth, this reporting is not correct," it said in a statement.

Daiichi Sankyo is focusing on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay blood pressure drug.

In the year through March 2019, the OTC unit generated 66.4 billion yen in sales. The group's total sales reached 930 billion yen.

The OTC unit makes popular energy drink Regain as well as Lulu Attack cold medicine and Gaster 10 stomach medicine.

(Reporting by Takashi Umekawa and Chang-Ran Kim; Editing by Stephen Coates and Christopher Cushing)

Stocks mentioned in the article
ChangeLast1st jan.
DAIICHI SANKYO COMPANY, LIMITED -0.29% 6814 End-of-day quote.98.95%
NIKKEI 225 0.25% 22548.9 Real-time Quote.12.18%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.05% 108.487 Delayed Quote.-1.17%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
10/16DAIICHI SANKYO : Announces Transfer from Astellas Pharma of Three Products in As..
AQ
09/27Kansai Electric president apologises for payments scandal
RE
09/27DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for interim dividend
FA
09/18Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatme..
AQ
09/17Trial of Tepco executives over Japan's Fukushima disaster heads to conclusion
RE
09/12DAIICHI SANKYO : Announces Launch of Oxycodone Extended Release Tablets NX 'Daii..
AQ
09/04AstraZeneca's Tagrisso gets China OK for type of lung cancer
RE
08/23GSK builds oncology pipeline as drug shown to help myeloma patients
RE
08/12Influenza Vaccines Market is Expected to Surpass USD 6 billion by 2025 | Key ..
AQ
08/08MCKESSON : TURALIO FDA Approved Treatment of TGCT, Available at Biologics by McK..
AQ
More news
Financials (JPY)
Sales 2020 965 B
EBIT 2020 124 B
Net income 2020 91 168 M
Finance 2020 327 B
Yield 2020 1,03%
P/E ratio 2020 48,5x
P/E ratio 2021 52,2x
EV / Sales2020 4,12x
EV / Sales2021 3,92x
Capitalization 4 297 B
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 7 750,00  JPY
Last Close Price 6 814,00  JPY
Spread / Highest target 46,8%
Spread / Average Target 13,7%
Spread / Lowest Target -19,3%
EPS Revisions
Managers
NameTitle
Joji Nakayama Chairman & Chief Executive Officer
Sunao Manabe President, COO & Representative Director
Toshiaki Sai CFO, Representative Director & Vice President
Junichi Koga Senior Managing Executive Officer, Global Head-R&D
Katsumi Fujimoto Director
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED98.95%40 683
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.10%198 751